{"doi":"10.1016/j.jalz.2015.05.004","title":"The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study designed to characterize the trajectories of biomarkers across the aging process. We present ADNI Biostatistics Core analyses that integrate data over the length, breadth, and depth of ADNI.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Relative progression of key imaging, fluid, and clinical measures was assessed. Individuals with subjective memory complaints (SMC) and early mild cognitive impairment (eMCI) were compared with normal controls (NC), MCI, and individuals with Alzheimer's disease. Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Relative progression of markers supports parts of the amyloid cascade hypothesis, although evidence of earlier occurrence of cognitive change exists. SMC are similar to NC, whereas eMCI fall between the cognitively normal and MCI groups. Amyloid leads to faster conversion and increased cognitive impairment.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Analyses support features of the amyloid hypothesis, but also illustrate the considerable heterogeneity in the aging process.</jats:p></jats:sec>","journal":"Alzheimer's &amp; Dementia","year":2015,"id":610104,"datarank":0.7023196840686331,"base_score":4.68213122712422,"endowment":4.68213122712422,"self_citation_contribution":0.7023196840686331,"citation_network_contribution":0.0,"self_endowment_contribution":0.7023196840686331,"citer_contribution":0.0,"corpus_percentile":71.6,"corpus_rank":3751,"citation_count":107,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":2,"is_dataset":true,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":51708,"name":"Michael C. Donohue","orcid":null,"position":1,"is_corresponding":false},{"id":472431,"name":"Cathy Wang","orcid":null,"position":2,"is_corresponding":false},{"id":232962,"name":"Paul Aisen","orcid":"0000-0002-2896-5838","position":3,"is_corresponding":false},{"id":1568481,"name":"Danielle J. Harvey","orcid":null,"position":4,"is_corresponding":false},{"id":484327,"name":"Naomi Saito","orcid":"0000-0003-4069-3721","position":5,"is_corresponding":false},{"id":1568480,"name":"Laurel A. Beckett","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study designed to characterize the trajectories of biomarkers across the aging process. We present ADNI Biostatistics Core analyses that integrate data over the length, breadth, and depth of ADNI.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Relative progression of key imaging, fluid, and clinical measures was assessed. Individuals with subjective memory complaints (SMC) and early mild cognitive impairment (eMCI) were compared with normal controls (NC), MCI, and individuals with Alzheimer's disease. Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Relative progression of markers supports parts of the amyloid cascade hypothesis, although evidence of earlier occurrence of cognitive change exists. SMC are similar to NC, whereas eMCI fall between the cognitively normal and MCI groups. Amyloid leads to faster conversion and increased cognitive impairment.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Analyses support features of the amyloid hypothesis, but also illustrate the considerable heterogeneity in the aging process.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":4.68213122712422,"endowment":4.68213122712422,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26194315","pmcid":null,"openalex_id":"https://openalex.org/W1482496268","authors":[],"funders":[{"funder_name":"National Institutes of Health","grant_id":"U01 AG024904","title":null},{"funder_name":"U.S. Department of Defense","grant_id":"W81XWH‐12‐2‐0012","title":null},{"funder_name":"W. Garfield Weston Foundation","grant_id":"5U01AG10483‐15","title":null},{"funder_name":"W. Garfield Weston Foundation","grant_id":"1U01AG24904‐01","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA093373","title":null},{"funder_name":"NIGMS NIH HHS","grant_id":"R01 GM088336","title":null},{"funder_name":"NIA NIH HHS","grant_id":"L30 AG040785","title":null},{"funder_name":"NICHD NIH HHS","grant_id":"U54 HD079125","title":null},{"funder_name":"NIA NIH HHS","grant_id":"RC2 AG036535","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P01 AG014449","title":null},{"funder_name":"NIA NIH HHS","grant_id":"U01 AG010483","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R01 AG047827","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P30 AG010129","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"R25 RR026008","title":null},{"funder_name":"NICHD NIH HHS","grant_id":"R01 HD042974","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P01 AG009466","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R01 AG012975","title":null},{"funder_name":"NINDS NIH HHS","grant_id":"U54 NS079202","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"UL1 RR024146","title":null},{"funder_name":" CIHR","grant_id":"","title":null}],"total_grants":20,"fwci":4.1846,"citation_percentile":0.94272315,"influential_citations":0,"citation_trend":[{"year":2015,"count":3},{"year":2016,"count":3},{"year":2017,"count":4},{"year":2018,"count":10},{"year":2019,"count":8},{"year":2020,"count":11},{"year":2021,"count":13},{"year":2022,"count":11},{"year":2023,"count":6},{"year":2024,"count":17},{"year":2025,"count":16},{"year":2026,"count":5}],"oa_status":"green","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4510463","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4510463","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S1552526015001703?httpAccept=text/plain","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1552526015001703?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1016%2Fj.jalz.2015.05.004","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2015.05.004","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1016/j.jalz.2015.05.004","host_type":"publisher"},{"url":"https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2015.05.004","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jalz.2015.05.004","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26194315","host_type":"repository"},{"url":"https://escholarship.org/uc/item/4mj5494v","host_type":"repository"}],"fields_of_study":["Dementia and Cognitive Impairment Research","Alzheimer's disease research and treatments","Functional Brain Connectivity Studies","Age Factors","Alzheimer Disease","Amyloid","Brain","Cognitive Dysfunction","Disease Progression","Humans","Longitudinal Studies","Memory Disorders","Mental Status Schedule","Multicenter Studies as Topic","Neuroimaging"],"mesh_terms":["Age Factors","Alzheimer Disease","Amyloid","Brain","Humans","Longitudinal Studies","Memory Disorders","Mental Status Schedule","Multicenter Studies as Topic","Disease Progression","Neuroimaging","Cognitive Dysfunction"],"keywords":["Neuroimaging","Alzheimer's Disease Neuroimaging Initiative","Cognition","Cognitive impairment","Magnetic resonance imaging","Amyloid (mycology)","Disease","Alzheimer's disease","Psychology","Neuroscience","Cognitive decline","Medicine","Dementia","Internal medicine","Pathology","Radiology","Amyloid cascade hypothesis","Subjective memory complaints"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.20363542.v1","title":"Additional file 1 of Grey matter changes on brain MRI in subjective cognitive decline: a systematic review","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20363542","title":"Additional file 1 of Grey matter changes on brain MRI in subjective cognitive decline: a systematic review","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T19:28:59.310856Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}